Penumbra stock gets fresh STORM-PE data catalyst

Penumbra, Inc. (ISIN US70975L1070) was last at USD 317.11 on the NYSE on October 5, 2026 at 4:00 p.m. ET, with a market capitalization of USD 12.5 billion. The company reported new STORM-PE trial data on October 6, 2026, giving the medical-device stock a fresh clinical milestone to assess.

STORM-PE expands recovery evidence

According to PR Newswire on October 6, 2026, Penumbra presented a subset analysis from STORM-PE at the Vascular InterVentional Advances meeting. The randomized trial enrolled 100 patients across 22 international sites and compared computer assisted vacuum thrombectomy plus anticoagulation with anticoagulation alone.

The analysis connected daily step counts, walking-bout measures and peak 10-minute activity with the six-minute walk test at 30 days. The correlation was strongest when wearable and clinic data were matched at 30 days, while the relationship weakened at 90 days, making the result relevant to real-world recovery but not a replacement for the trial's clinical endpoints.

Revenue grows as profit declines

Markets Insider reported that Penumbra's second-quarter revenue reached USD 390.05 million for the period ended June 30, 2026, up 14.9 percent from USD 339.46 million a year earlier. Net profit was USD 34.81 million, down 23.1 percent from USD 45.27 million in the prior-year quarter.

That combination matters for the stock's valuation: the top line continues to expand, but the earnings base is moving in the opposite direction. The same report said adjusted? No, it described reported quarterly figures, so the comparison remains on a reported basis rather than mixing actual results with estimates.

Analyst target stays above the stock

In a report released on October 1, 2026, RBC Capital maintained a Hold rating and a USD 374.00 price target, as reported by Markets Insider on October 2, 2026. The target lies 17.9 percent above the USD 317.11 price on October 5, 2026.

The company release also identified the pending acquisition by Boston Scientific as a risk that could affect operations before completion, alongside regulatory approval, product-development and clinical-trial risks. That balance leaves investors weighing new evidence on pulmonary-embolism treatment against execution and transaction uncertainty.

Penumbra stock stays below yearly high

Penumbra stock was last at USD 317.11 on the NYSE on October 5, 2026 at 4:00 p.m. ET. Its 52-week range was USD 221.26 to USD 362.41, leaving the quoted price USD 45.30 below the high.

Upcoming dates for Penumbra stock

• November 4, 2026: Quarterly earnings

More news and analyses on Penumbra stock